题名

Long-term Safety, Efficacy, Treatment Satisfaction, and Impact on Healthcare Service Use of Paliperidone Palmitate One-month Intramuscular Formulation in Patients with Recent-onset Schizophrenia in Taiwan: A Subgroup Analysis of an Asia-Pacific, 18-month, Phase 3b Study

DOI

10.4103/TPSY.TPSY_39_19

作者

Tze-Chun Tang;Ming-Hong Hsieh;Chen-Chung Liu;Nan-Ying Chiu;Fong-Lin Jang;Chih-Lin Chiang;Tung-Ping Su

关键词

clinical trial ; employment status ; long-acting injection ; schizophrenia

期刊名称

台灣精神醫學

卷期/出版年月

33卷4期(2019 / 12 / 01)

页次

198 - 203

内容语文

英文

中文摘要

Objectives: In this study, the authors intended to evaluate the efficacy and safety of paliperidone palmitate 1-month injection (PP1M) in patients with recent-onset schizophrenia (SCH). Methods: A subgroup analysis was done for patients enrolled in Taiwan in an Asia-Pacific, Phase 3b study (ClinicalTrials.gov identifier NCT01051531). Patients were switched from oral antipsychotics to intramuscular PP1M. Results: We included 61 patients (age: 31.2 ± 8.8 years). The Positive and Negative Syndrome Scale scores were significantly decreased, with the largest effect size observed in positive, disorganized, and depressive factors (Cohen's d = 0.52, 0.52, and 0.79, respectively). Most symptoms stabilized within six months, whereas stabilization of functional improvement required 1-1.5 years of PP1M treatment, especially for employment/ academic status. PP1M treatment was well-tolerated, with over 70% of treatment satisfaction rate, and significantly reduced the average days of hospitalization (43.3-7.1/person-years). Conclusion: Switching to PP1M improved treatment outcome and satisfaction as well as reduced healthcare service use in patients with recent-onset SCH.

主题分类 醫藥衛生 > 社會醫學
参考文献
  1. Huang, SS,Chang, CC(2019).Comparison of insight in patients with schizophrenia, bipolar I disorder, and major depressive disorder in a real-world setting.Taiwan J Psychiatry,33,92-98.
    連結:
  2. Alphs, L,Bossie, CA,Sliwa, JK(2013).Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.Neuropsychiatr Dis Treat,9,341-350.
  3. Birnbaum, M,Sharif, Z(2008).Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.Patient Prefer Adherence,2,233-240.
  4. Chi, MH,Hsiao, CY,Chen, KC(2016).The readmission rate and medical cost of patients with schizophrenia after first hospitalization – a 10-year follow-up population-based study.Schizophr Res,170,184-190.
  5. Chiang, CL,Chen, PC,Huang, LY(2016).Impact of universal health coverage on urban-rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan.BMJ Open,6,e010802.
  6. Fu, DJ,Turkoz, I,Simonson, RB(2016).Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder.J Clin Psychopharmacol,36,372-376.
  7. Fu, DJ,Turkoz, I,Simonson, RB(2015).Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.J Clin Psychiatry,76,253-262.
  8. Jin, H,Mosweu, I(2017).The societal cost of schizophrenia: a systematic review.Pharmacoeconomics,35,25-42.
  9. Kishimoto, T,Nitta, M,Borenstein, M(2013).Long-acting injectableversus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.J Clin Psychiatry,74,957-965.
  10. Lêng, CH,Chou, MH,Lin, SH(2016).Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan.Schizophr Res,171,97-102.
  11. Lo, TL,Warden, M,He, Y(2016).Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.Asia Pac Psychiatry,8,154-171.
  12. Malla, A,Tibbo, P,Chue, P(2013).Long-acting injectable antipsychotics: recommendations for clinicians.Can J Psychiatry,58,30S-35S.
  13. Millier, A,Schmidt, U,Angermeyer, MC(2014).Humanistic burden in schizophrenia: a literature review.J Psychiatr Res,54,85-93.
  14. Olivares, JM,Thirunavukarasu, M,Kulkarni, J(2013).Psychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-pacific survey.Neuropsychiatr Dis Treat,9,1163-1170.
  15. Pan, YJ,Kuo, KH,Yeh, LL(2019).Healthcare cost, service use and mortality in major psychiatric disorders in Taiwan.J Affect Disord,246,112-120.
  16. Samalin, L,Abbar, M,Courtet, P(2013).French society for biological psychiatry and neuropsychopharmacology task force: formal consensus for the prescription of depot antipsychotics.Encephale,39(Suppl 4),189-203.
  17. Schreiner, A,Bergmans, P,Cherubin, P(2015).Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.J Psychopharmacol,29,910-922.
  18. Su, KP,Chang, HC,Tsai, SJ(2009).Relapse and long-acting injectablerisperidone: a 1-year mirror image study with a national claims database in Taiwan.Value Health,12(Suppl 3),118-121.
  19. Taipale, H,Mehtälä, J,Tanskanen, A(2018).Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-A nationwide study with 20-year follow-up.Schizophr Bull,44,1381-1387.
  20. Tiihonen, J,Mittendorfer-Rutz, E,Majak, M(2017).Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia.JAMA Psychiatry,74,686-693.
  21. Turkoz, I,Fu, DJ,Bossie, CA(2015).The direct and indirect effects of paliperidone extended-release on depressive symptoms in schizoaffective disorder: a path analysis.Innov Clin Neurosci,12,10-17.
  22. Wallwork, RS,Fortgang, R,Hashimoto, R(2012).Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.Schizophr Res,137,246-250.
  23. Zhang, F,Si, T,Chiou, CF(2015).Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.Neuropsychiatr Dis Treat,11,657-668.
  24. Zhang, H,Turkoz, I,Zhuo, J(2017).Paliperidone palmitate improves and maintains functioning in Asia-pacific patients with schizophrenia.Adv Ther,34,2503-2517.